NCT07437963 2026-03-19
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
National Cancer Institute (NCI)
Phase 1/2 Not yet recruiting
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Medical College of Wisconsin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Epitopoietic Research Corporation